Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Prostate cancer. Found 50 abstracts

no pagination
O'Malley DM, Hudson SV, Ohman-Strickland PA, Bator A, Lee HS, Gundersen DA, Miller SM. Follow-up Care Education and Information: Identifying Cancer Survivors in Need of More Guidance. Journal of Cancer Education. 2016 Mar;31(1):63-9.   PMCID: PMC4475492
Shaikh T, Wang L, Ruth K, Hallman M, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2016 Jan 29;15(2):156-62.   PMCID: PMC4789160
Zaorsky NG, Shaikh T, Murphy CT, Hallman MA, Hayes SB, Sobczak ML, Horwitz EM. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev. 2016 Jun 17;48:50-60.
Aiken WD, Jones KS, Ragin C, James K. Rural-urban differences in the clinico-pathologic profiles of Jamaican men with prostate cancer. Infect Agent Cancer. 2015 Jan;10:32.   PMCID: 4584435
Hall MJ, Ruth KJ, Chen DY, Gross LM, Giri VN. Interest in genomic SNP testing for prostate cancer risk: a pilot survey. Hered Cancer Clin Pract. 2015 Jan;13(1):11.   PMCID: 4396119
Haseebuddin M, Smaldone MC. Treatment of localized prostate cancer in elderly patients. Gland Surg. 2015 Aug;4(4):283-7.   PMCID: PMC4523629
Martin JM, Handorf EA, Price RA, Cherian G, Buyyounouski MK, Chen DY, Kutikov A, Johnson ME, Ma CC, Horwitz EM. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Medical Dosimetry. 2015 Jan;40(3):186-9.   PMCID: 4500753
Miller SM, Hudson SV, Hui SK, Diefenbach MA, Fleisher L, Raivitch S, Belton T, Roy G, Njoku A, Scarpato J, Viterbo R, Buyyounouski M, Denlinger C, Miyamoto C, Reese A, Baman J. Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment. Journal of Cancer Survivorship. 2015 Sep;9(3):541-53.   PMCID: 4537811
Shaikh T, Zaorsky NG, Ruth K, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy. 2015 Jan;14(3):316-21.   PMCID: 4424094
Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015 May 28;115(3):295-300.
Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK. Does family history of prostate cancer affect outcomes following radiotherapy?. Radiotherapy and Oncology. 2014 Feb;110(2):229-34.   PMCID: 3991234
Handorf E, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal of Genetic Counseling. 2014 Jun;23(3):371-6.   PMCID: PMC4028414
Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Sep;13(5):456-64.
Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19.   PMCID: not NIH funded
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439.   PMCID: not NIH funded
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301.   PMCID: NIHMS285956
Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):445-52.   PMCID: PMC2952349
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radation therapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2010 Feb;76(2):361-8.   PMCID: PMC2847420
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22.   PMCID: PMCID: PMC2920356 [Available on 2011/12/1]
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Prostate cancer

Prostate cancer Brachytherapy phase-iii trial radiotherapy Radiation therapy neoadjuvant Clinical trials radical prostatectomy Dosimetry Survivorship Treatment Outcome Family history Prostatic Neoplasms Prognostic factors Technology Quality assurance Male adjuvant Radiotherapy Dosage locally advanced-carcinoma methods competing risk Radiotherapy external-beam radiotherapy androgen deprivation Rural population Organ Size Resident Black men Androgen Conformal radiation therapy C-SHIP model Health literacy Radiation Protection Radiation Exposure definitive radiotherapy HOXB13 ASSOCIATION Nuclear Medicine & Medical Imaging Radiology Prostate analysis randomized trial seed implantation Standard External beam radiation therapy biochemical failure African American Genetic mutations risk adverse effects LDR GERMLINE MUTATIONS INCREASED RISK Hypoxia Informational needs Awareness postimplant Genomic testing acute urinary Kaplan-Meier Estimate predict pathological stage Testicle dose Serum testosterone CARRIERS Medical student androgen suppression BRCA1 Radiation Absorption Risk assessment Testis Outcomes dosimetric analysis cancer patients Oncology Adult Volumetric-modulated arc therapy gleason score Single-nucleotide polymorphism Middle Aged blood Web-based health intervention development Multivariate Analysis deprivation therapy Radiotherapy dose fractionation Guideline greater-than-20 pubic arch interference algorithm Health services accessibility radiation-therapy Eppendorf Early detection of cancer quality-of-life Genetics & Heredity hormonal-therapy Proportional Hazards Models Tumor Biomarkers Safety ml Hormonal ablation body-mass index Postoperative Ldr Patient activation Training Androgen deprivation therapy angiogenesis Intensity-Modulated Radiotherapy 1980 aryulu kkn-international journal of radiation oncology biology physics-v6-p1261 men Low-dose rate androgen deprivation therapy Health disparities Interstitial Hormonal therapy GENE Biochemical failure D90 survival Adenocarcinoma replacement therapy conformal radiation-therapy V100 Intensity-modulated radiotherapy retention Breast cancer pathological stage elderly patients Retrospective Studies Radiation oncology competing group protocol 92-02 Quality of life dose-escalation trial population Age expression radiation effects Health adaptation and surveillance carcinoma hypogonadal men Biochemical control Gastrointestinal toxicity oxygenation tumor Proton therapy anatomy & histology Follow-up suppression volume histogram analysis
Last updated on Friday, December 06, 2019